NCT01286207View on ClinicalTrials.gov

Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,959

Participants

Timeline

Start Date

March 31, 1995

Primary Completion Date

May 31, 1997

Study Completion Date

May 31, 1997

Conditions

Migraine Disorders

Interventions

DRUG

Rizatriptan 5 mg

Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)

DRUG

Rizatriptan 10 mg

Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)

DRUG

Standard Care

Active standard care

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT01286207 - Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029) | Biotech Hunter | Biotech Hunter